Patents by Inventor Ishan Capila

Ishan Capila has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7592152
    Abstract: The invention relates to chondroitinase ABC I and uses thereof. In particular, the invention relates to recombinant and modified chondroitinase ABC I, their production and their uses. The chondroitinase ABC I enzymes of the invention are useful for a variety of purposes, including degrading and analyzing polysaccharides such as glycosaminoglycans (GAGs). These GAGs can include chondroitin sulfate, dermatan sulfate, unsulfated chondroitin and hyaluronan. The chondroitinase ABC I enzymes can also be used in therapeutic methods such as promoting nerve regeneration, promoting stroke recovery, treating spinal cord injury, treating epithelial disease, treating infections and treating cancer.
    Type: Grant
    Filed: December 13, 2006
    Date of Patent: September 22, 2009
    Assignee: Massachusetts Institute of Technology
    Inventors: Vikas Prabhakar, Ishan Capila, Rahul Raman, Carlos Bosques, Kevin Pojasek, Ram Sasisekharan
  • Patent number: 7553950
    Abstract: The invention relates to chondroitinase ABC I and uses thereof. In particular, the invention relates to recombinant and modified chondroitinase ABC I, their production and their uses. The chondroitinase ABC I enzymes of the invention are useful for a variety of purposes, including degrading and analyzing polysaccharides such as glycosaminoglycans (GAGs). These GAGs can include chondroitin sulfate, dermatan sulfate, unsulfated chondroitin and hyaluronan. The chondroitinase ABC I enzymes can also be used in therapeutic methods such as promoting nerve regeneration, promoting stroke recovery, treating spinal cord injury, treating epithelial disease, treating infections and treating cancer.
    Type: Grant
    Filed: December 13, 2006
    Date of Patent: June 30, 2009
    Assignee: Massachusetts Institute of Technology
    Inventors: Vikas Prabhakar, Ishan Capila, Rahul Raman, Carlos Bosques, Kevin Pojasek, Ram Sasisekharan
  • Patent number: 7507570
    Abstract: The invention relates to chondroitinase ABC I and uses thereof. In particular, the invention relates to recombinant and modified chondroitinase ABC I, their production and their uses. The chondroitinase ABC I enzymes of the invention are useful for a variety of purposes, including degrading and analyzing polysaccharides such as glycosaminoglycans (GAGs). These GAGs can include chondroitin sulfate, dermatan sulfate, unsulfated chondroitin and hyaluronan. The chondroitinase ABC I enzymes can also be used in therapeutic methods such as promoting nerve regeneration, promoting stroke recovery, treating spinal cord injury, treating epithelial disease, treating infections and treating cancer.
    Type: Grant
    Filed: March 10, 2005
    Date of Patent: March 24, 2009
    Assignee: Massachusetts Institute of Technology
    Inventors: Vikas Prabhakar, Ishan Capila, Rahul Raman, Carlos Bosques, Kevin Pojasek, Ram Sasisekharan
  • Publication number: 20070287683
    Abstract: Preparations of low molecular weight heparins (LMWHs) having improved properties, e.g., properties that provide a clinical advantage, are provided herein. Methods of making and using such preparations as well as methods of analyzing starting materials, processing, intermediates and final products in the production of such LMWH preparations are provided.
    Type: Application
    Filed: May 24, 2007
    Publication date: December 13, 2007
    Inventors: Zachary Shriver, Mallikarjun Sundaram, Ganesh Venkataraman, Pat Oliver-Shaffer, Yiming Yao, Zainab Mamuwala, Ian Fier, Yiwei Qi, Ishan Capila, Nur Gunay, Daniela Beccati, Cuihua Liu, Corinne Bauer, Ying Li
  • Publication number: 20070224670
    Abstract: The invention relates to chondroitinase ABC I and uses thereof. In particular, the invention relates to recombinant and modified chondroitinase ABC I, their production and their uses. The chondroitinase ABC I enzymes of the invention are useful for a variety of purposes, including degrading and analyzing polysaccharides such as glycosaminoglycans (GAGs). These GAGs can include chondroitin sulfate, dermatan sulfate, unsulfated chondroitin and hyaluronan. The chondroitinase ABC I enzymes can also be used in therapeutic methods such as promoting nerve regeneration, promoting stroke recovery, treating spinal cord injury, treating epithelial disease, treating infections and treating cancer.
    Type: Application
    Filed: December 13, 2006
    Publication date: September 27, 2007
    Applicant: Massachusetts Institute of Technology
    Inventors: Vikas Prabhakar, Ishan Capila, Rahul Raman, Carlos Bosques, Kevin Pojasek, Ram Sasisekharan
  • Publication number: 20070202563
    Abstract: The invention relates to chondroitinase ABC I and uses thereof. In particular, the invention relates to recombinant and modified chondroitinase ABC I, their production and their uses. The chondroitinase ABC I enzymes of the invention are useful for a variety of purposes, including degrading and analyzing polysaccharides such as glycosaminoglycans (GAGs). These GAGs can include chondroitin sulfate, dermatan sulfate, unsulfated chondroitin and hyaluronan. The chondroitinase ABC I enzymes can also be used in therapeutic methods such as promoting nerve regeneration, promoting stroke recovery, treating spinal cord injury, treating epithelial disease, treating infections and treating cancer.
    Type: Application
    Filed: December 13, 2006
    Publication date: August 30, 2007
    Applicant: Massachusetts Institute of Technology
    Inventors: Vikas Prabhakar, Ishan Capila, Rahul Raman, Carlos Bosques, Kevin Pojasek, Ram Sasisekharan
  • Publication number: 20070148157
    Abstract: The invention relates to chondroitinase ABC I and uses thereof. In particular, the invention relates to recombinant and modified chondroitinase ABC I, their production and their uses. The chondroitinase ABC I enzymes of the invention are useful for a variety of purposes, including degrading and analyzing polysaccharides such as glycosaminoglycans (GAGs). These GAGs can include chondroitin sulfate, dermatan sulfate, unsulfated chondroitin and hyaluronan. The chondroitinase ABC I enzymes can also be used in therapeutic methods such as promoting nerve regeneration, promoting stroke recovery, treating spinal cord injury, treating epithelial disease, treating infections and treating cancer.
    Type: Application
    Filed: December 13, 2006
    Publication date: June 28, 2007
    Applicant: Massachusetts Institute of Technology
    Inventors: Vikas Prabhakar, Ishan Capila, Rahul Raman, Carlos Bosques, Kevin Pojasek, Ram Sasisekharan
  • Publication number: 20070148740
    Abstract: The invention relates to chondroitinase ABC I and uses thereof. In particular, the invention relates to recombinant and modified chondroitinase ABC I, their production and their uses. The chondroitinase ABC I enzymes of the invention are useful for a variety of purposes, including degrading and analyzing polysaccharides such as glycosaminoglycans (GAGs). These GAGs can include chondroitin sulfate, dermatan sulfate, unsulfated chondroitin and hyaluronan. The chondroitinase ABC I enzymes can also be used in therapeutic methods such as promoting nerve regeneration, promoting stroke recovery, treating spinal cord injury, treating epithelial disease, treating infections and treating cancer.
    Type: Application
    Filed: December 13, 2006
    Publication date: June 28, 2007
    Applicant: Massachusetts Institute of Technology
    Inventors: Vikas Prabhakar, Ishan Capila, Rahul Raman, Carlos Bosques, Kevin Pojasek, Ram Sasisekharan
  • Publication number: 20070053845
    Abstract: Nanocells allow the sequential delivery of two different therapeutic agents with different modes of action or different pharmacokinetics. A nanocell is formed by encapsulating a nanocore with a first agent inside a lipid vesicle containing a second agent. The agent in the outer lipid compartment is released first and may exert its effect before the agent in the nanocore is released. The nanocell delivery system may be formulated in pharmaceutical composition for delivery to patients suffering from diseases such as cancer, inflammatory diseases such as asthma, autoimmune diseases such as rheumatoid arthritis, infectious diseases, and neurological diseases such as epilepsy. In treating cancer, a traditional antineoplastic agent is contained in the outer lipid vesicle of the nanocell, and an antiangiogenic agent is loaded into the nanocore. This arrangement allows the antineoplastic agent to be released first and delivered to the tumor before the tumor's blood supply is cut off by the antianiogenic agent.
    Type: Application
    Filed: July 28, 2006
    Publication date: March 8, 2007
    Inventors: Shiladitya Sengupta, Ganlin Zhao, Ishan Capila, David Eavarone, Ram Sasisekharan
  • Publication number: 20060078959
    Abstract: The invention relates to chondroitinase ABC I and uses thereof. In particular, the invention relates to recombinant and modified chondroitinase ABC I, their production and their uses. The chondroitinase ABC I enzymes of the invention are useful for a variety of purposes, including degrading and analyzing polysaccharides such as glycosaminoglycans (GAGs). These GAGs can include chondroitin sulfate, dermatan sulfate, unsulfated chondroitin and hyaluronan. The chondroitinase ABC I enzymes can also be used in therapeutic methods such as promoting nerve regeneration, promoting stroke recovery, treating spinal cord injury, treating epithelial disease, treating infections and treating cancer.
    Type: Application
    Filed: March 10, 2005
    Publication date: April 13, 2006
    Applicant: Massachusetts Institute of Technology
    Inventors: Vikas Prabhakar, Ishan Capila, Rahul Raman, Carlos Bosques, Kevin Pojasek, Ram Sasisekharan
  • Publication number: 20050266067
    Abstract: Nanocells allow the sequential delivery of two different therapeutic agents with different modes of action or different pharmacokinetics. A nanocell is formed by encapsulating a nanocore with a first agent inside a lipid vesicle containing a second agent. The agent in the outer lipid compartment is released first and may exert its effect before the agent in the nanocore is released. The nanocell delivery system may be formulated in pharmaceutical composition for delivery to patients suffering from diseases such as cancer, inflammatory diseases such as asthma, autoimmune diseases such as rheumatoid arthritis, infectious diseases, and neurological diseases such as epilepsy. In treating cancer, a traditional antineoplastic agent is contained in the outer lipid vesicle of the nanocell, and an antiangiogenic agent is loaded into the nanocore. This arrangement allows the antineoplastic agent to be released first and delivered to the tumor before the tumor's blood supply is cut off by the antianiogenic agent.
    Type: Application
    Filed: March 2, 2005
    Publication date: December 1, 2005
    Inventors: Shiladitya Sengupta, Ganlin Zhao, Ishan Capila, David Eavarone, Ram Sasisekharan